Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Apr 12;34(3):401-404.
doi: 10.1515/jbcpp-2023-0051. eCollection 2023 May 1.

The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib

Gioacchino Catania  1 , Rita Tavarozzi  1   2 , Giacomo Maria Pini  3 , Tiziana Borra  3 , Carolina Gandolfo  1 , Giulia Zacchi  1 , Daniela Pietrasanta  1 , Federico Monaco  1 , Manuela Zanni  1 , Maddalena Lettieri  4 , Paolo Rivela  1   2 , Francesco Zallio  1 , Marco Ladetto  1   2
Affiliations
Case Reports

The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib

Gioacchino Catania et al. J Basic Clin Physiol Pharmacol. .

Abstract

Objectives: The use of Bruton's tyrosine kinase (BTK) inhibitors has changed the clinical history of patients with chronic lymphocytic leukemia (CLL) in both naïve and relapsed/refractory settings. "Accelerated" chronic lymphocytic leukemia (a-CLL) is a relatively rare form of CLL representing less than 1 % of all CLL cases. a-CLL patients usually have a more aggressive course and a reduced overall survival was reported with conventional chemo-immunotherapy approaches.

Methods: The role of Bruton Tyrosine Kinase-inhibitor, ibrutinib, in a-CLL is well established with encouraging preliminary results.

Results: We report a case of a-CLL-treated first-line with second-generation BTKi, acalabrutinib with a prompt clinical response. As known, it is the first literature report on acalabrutinib in a-CLL highlighting the role of second-generation BTKi also in this high-risk setting.

Conclusions: Target therapies (Bruton Kinase inhibitors and Bcl2 inhibitors) have improved the therapeutic landscape of CLL. The availability of therapeutic targets requires greater diagnostic accuracy to choose the most appropriate therapy for each patient.

Keywords: Bruton kinase inhibitors; leukemia; precision medicine; target therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Kipps, TJ, Stevenson, FK, Wu, CJ, Croce, CM, Packham, G, Wierda, WG, et al.. Chronic lymphocytic leukaemia. Nat Rev Dis Prim 2017;3:16096. https://doi.org/10.1038/nrdp.2016.96 . - DOI
    1. Hallek, M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol 2019;94:1266–87. https://doi.org/10.1002/ajh.25595 . - DOI
    1. THerndon, TM, Chen, SS, Saba, NS, Valdez, J, Emson, C, Gatmaitain, M, et al.. Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. Leuk 2017;31:1340–7. https://doi.org/10.1038/leu.2017.11 . - DOI
    1. Gine, E, Martinez, A, Villamor, N, Lopez-Guillermo, A, Camos, M, Martinez, J, et al.. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 2010;95:1526–33. https://doi.org/10.3324/haematol.2009.022277 . - DOI
    1. Xie, J, Jang, A, Vegel, A, Hajja, Y, Mouawad, Y, Baghiani, A, et al.. Successful treatment of “accelerated” chronic lymphocytic leukemia with single agent ibrutinib: a report of two cases. Leukemia Res Rep 2021;15:100247. https://doi.org/10.1016/j.lrr.2021.100247 . - DOI

Publication types

MeSH terms

LinkOut - more resources